Duluth, GA – July 28, 2014 – Merial has announced the availability of PUREVAX® Feline Rabies 3 YR – the newest addition to the only nonadjuvanted line of feline vaccines and the first nonadjuvanted feline rabies vaccine with a 3 year Duration Of Immunity (DOI) to be marketed in the world.

Rabies is a known public health issue, as it is a contagious, lethal disease in animals that can be transmitted to humans. Fortunately, rabies is easily preventable through vaccination. In 2010, 6,154 cases of rabies in animals, and 2 human cases were reported in the US and Puerto Rico. While wildlife have accounted for 90% of rabies cases in the US, of the animal cases reported, nearly 5% were feline. In fact, currently in the US, cats are nearly five times more likely to be diagnosed with rabies compared to dogs.1

“Merial is proud to be able to offer a nonadjuvanted rabies vaccine with a 3 year DOI. The recombinant technology that has also been used to produce other vaccines, such as the 1 year PUREVAX rabies and FELV, allows the development of effective vaccines for feline viral diseases (where modified live vaccines are not feasible) without the need for adjuvants. We are committed to innovation to better the health and well-being of animals.”

Dr. Leigh O’Mara, Associate Director of Technical Marketing, US Pets Vaccines, Merial

The addition of the recombinant, nonadjuvanted rabies 3 year vaccine allows veterinarians a new option in the management of their feline rabies prevention programs. Veterinarians in states that mandate the use of a multi-year DOI rabies vaccine now have access to a nonadjuvanted product for their feline patients. In addition, veterinarians now no longer have to choose between a multi-year adjuvanted rabies vaccine and an annual nonadjuvanted rabies vaccine for clients who do not reliably return to the clinic annually.

Merial developed PUREVAX Feline Rabies 3 YR in response to veterinarians’ demand for a nonadjuvanted rabies vaccine with a 3 year DOI. PUREVAX Feline Rabies 3 YR has been proven effective in the face of severe challenge. This vaccine utilizes recombinant canarypox-vectored technology which stimulates both humoral and cell-mediated immunity and has proven effective in the face of severe challenge.

PUREVAX Feline Rabies 3 YR is recommended for the vaccination of healthy cats 12 weeks and older for prevention of disease due to the rabies virus. A 1 year booster vaccination is required after primary vaccination, followed by a vaccination every three years.

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 6,000 people and operates in more than 150 countries worldwide. In 2013, its sales were $2 billion. For more information, please see www.merial.com.

Merial is a Sanofi company.

®PUREVAX is a registered trademark of Merial. ©2014 Merial Limited, Duluth, GA. All rights reserved. PUR143YRRABIESPR (07/14)

For further information please contact:

Natasha Mahanes
Tel: 678-638-3690


1. Blanton et al. Rabies surveillance in the United States during 2010. JAVMA, 2011; 239 (6) 773-783

2. Merial Data on File

3. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995; 13;6;539-549